Pharmaceuticals News and Research

RSS

New clinical trial to evaluate HSP90 inhibitor plus hormonal therapy for breast cancer

Pushed to the brink of survival, the hyper-driven cells of a cancerous tumor tap into an ancient system that has helped organisms cope with internal stresses and environmental challenges since life began. As an integral part of this system, heat shock protein 90 (HSP90) has been shown to help malignant cells accommodate the genetic changes and profound disturbances in normal biology that occur in cancers.

23 May 2012

HVTN opens enrollment in GeoVax’s GM-CSF adjuvanted vaccine Phase 1 trial for HIV

GeoVax Labs, Inc., an Atlanta-based biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, today announced that the NIH-funded HIV Vaccine Trials Network (HVTN) has opened enrollment for a Phase 1 trial for the company's second-generation HIV vaccine.

23 May 2012

Fake, substandard malaria drugs threatening gains made in fight against disease, NIH study warns

"Low-quality and fake anti-malarial drugs flooding into markets in Asia and Africa are driving drug resistance and threatening gains made in the fight against the disease in the past decade, according to a study" conducted by researchers at the National Institutes of Health (NIH) and published Monday in the journal Lancet Infectious Diseases, Reuters reports.

23 May 2012

Science journal’s NEWSFOCUS section describes recent advances in sequencing technology

Rapid DNA sequencing may soon become a routine part of each individual's medical record, providing enormous information previously sequestered in the human genome's 3 billion nucleotide bases. This week's NEWSFOCUS section of the journal Science describes recent advances in sequencing technology.

From Oxford Nanopore Technologies 23 May 2012

Results from Boehringer Ingelheim’s Respimat Phase II study on moderate, persistent asthma

Boehringer Ingelheim announced today results from a Phase II study evaluating the investigational compound tiotropium delivered once-daily via the Respimat Inhaler in adolescents with symptomatic, moderate persistent asthma.

23 May 2012

Prodigy Generics launches injectable irinotecan

Prodigy Generics, a division of Prodigy Health Supplier Corporation (PHS), has launched injectable irinotecan. Irinotecan is the generic equivalent of the branded drug Camptosar by Pfizer.

23 May 2012

Researchers identify new mechanism for drug-related autoimmune reactions

A team of researchers led by the U.S. Food and Drug Administration has discovered a new mechanism for identifying and understanding drug-related autoimmune reactions.

23 May 2012

Data from Alvine’s ALV003 Phase 2A trial on celiac disease presented at DDW 2012

Alvine Pharmaceuticals, Inc. today announced the presentation of data from a Phase 2A trial of its lead compound, ALV003, at the 2012 Digestive Diseases Week (DDW) meeting held in San Diego, California. The study results met the primary endpoint of demonstrating that oral ALV003, administered in the context of a gluten free diet (GFD), can diminish gluten-induced intestinal mucosal injury in well-controlled celiac disease patients. The company plans to initiate a Phase 2B trial later this year.

23 May 2012

AB SCIEX, Prosolia enter technology license agreement

Prosolia, Inc. and AB SCIEX announced today that they have entered into a license agreement for technologies developed by Dr. Gary Van Berkel and his colleagues of Oak Ridge National Laboratory.

From Thermo Fisher Scientific Inc. 22 May 2012

Gattex may represent new treatment approach for short bowel syndrome

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today reported the presentation of data at the Digestive Disease Week (DDW) meeting held May 19-22 in San Diego.

22 May 2012

Thermo Scientific Watson LIMS offers enhanced functionality for bioanalytical laboratories

Thermo Fisher Scientific Inc., the world leader in serving science, today announced that its Thermo Scientific Watson LIMS (laboratory information management system) offers enhanced functionality for large molecule bioanalysis in pharmaceutical and contract research organization (CRO) laboratories.

From Thermo Fisher Scientific Inc. 22 May 2012

“Sandwich” immunoassay used to search for new chemical reactions

Many discoveries are made by chance, but it is also possible to help it along: The chance of finding something interesting increases when the number of experiments rises. French researchers have now applied this principle to the search for new chemical reactions. In the journal Angewandte Chemie, they have introduced a new concept based on antibodies and a “sandwich” immunoassay.

22 May 2012

Bill introduced in U.S. Senate is latest push to award prizes for new drug development

"As Washington prepares for a major international AIDS conference this summer, developments on the drug front are once again elevating the subject of the continuing epidemic in the public eye," CQ HealthBeat reports.

22 May 2012

Bayer’s Nexavar Phase 3 trial on NSCLC does not meet primary endpoint

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that a Phase 3 trial evaluating Nexavar (sorafenib) tablets in patients with advanced relapsed or refractory non-squamous non-small cell lung cancer (NSCLC) whose disease progressed after two or three previous treatments, did not meet its primary endpoint of improving overall survival.

22 May 2012

New research reveals effective treatments for gastrointestinal conditions

New research being presented at Digestive Disease Week- (DDW) reveals effective treatments for a number of gastrointestinal conditions, which are often chronic and costly.

22 May 2012

TransCytos, Enginasion collaborate to develop new transfection technology

Enginasion and TransCytos announced today that their collaboration has resulted in a prototype 'transfection' technology that is designed to have a dramatic and positive impact on the drug-research industry.

22 May 2012

InterMune reaches definitive agreement with Vidara to sell Actimmune

InterMune, Inc. today announced that it has reached a definitive agreement with Vidara Therapeutics International Limited (Vidara) to sell its rights to Actimmune (interferon gamma-1b) in a cash transaction valued at $55 million plus a two-year royalty stream.

22 May 2012

CHDI, Lundbeck enter collaboration to investigate targeted therapy for Huntington's disease

CHDI Foundation, Inc. and Lundbeck today announced a research collaboration to investigate a targeted therapy for Huntington's disease (HD). Currently, no treatment exists to slow or halt the progression of HD, a challenging hereditary neurodegenerative disease characterized by a triad of behavioral, cognitive, and motor symptoms.

21 May 2012

AltheRx reports positive Phase II results of Solabegron for OAB

AltheRx Pharmaceuticals, a privately-held clinical development company, presented positive results from its Phase II study of Solabegron in overactive bladder (OAB) at the American Urological Association Annual Meeting (Abstract # 520).

21 May 2012

Pernix Therapeutics introduces Omeclamox-Pak® for the treatment of H. pylori infection and duodenal ulcer disease

Pernix Therapeutics Holdings, Inc. (NYSE Amex: PTX), a specialty pharmaceutical company, today announced the introduction of Omeclamox-Pak®, a ten-day therapy of omeprazole delayed-release capsules (20 mg), clarithromycin tablets (500 mg) and amoxicillin capsules (500 mg) for the treatment of Helicobacter pylori (H. pylori) infection and duodenal ulcer disease (active or one-year history) to eradicate H. pylori in adult patients.

21 May 2012

Pharmaceuticals News and Research

New clinical trial to evaluate HSP90 inhibitor plus hormonal therapy for breast cancer

HVTN opens enrollment in GeoVax’s GM-CSF adjuvanted vaccine Phase 1 trial for HIV

Fake, substandard malaria drugs threatening gains made in fight against disease, NIH study warns

Science journal’s NEWSFOCUS section describes recent advances in sequencing technology

Results from Boehringer Ingelheim’s Respimat Phase II study on moderate, persistent asthma

Prodigy Generics launches injectable irinotecan

Researchers identify new mechanism for drug-related autoimmune reactions

Data from Alvine’s ALV003 Phase 2A trial on celiac disease presented at DDW 2012

AB SCIEX, Prosolia enter technology license agreement

Gattex may represent new treatment approach for short bowel syndrome

Thermo Scientific Watson LIMS offers enhanced functionality for bioanalytical laboratories

“Sandwich” immunoassay used to search for new chemical reactions

Bill introduced in U.S. Senate is latest push to award prizes for new drug development

Bayer’s Nexavar Phase 3 trial on NSCLC does not meet primary endpoint

New research reveals effective treatments for gastrointestinal conditions

TransCytos, Enginasion collaborate to develop new transfection technology

InterMune reaches definitive agreement with Vidara to sell Actimmune

CHDI, Lundbeck enter collaboration to investigate targeted therapy for Huntington's disease

AltheRx reports positive Phase II results of Solabegron for OAB

Pernix Therapeutics introduces Omeclamox-Pak® for the treatment of H. pylori infection and duodenal ulcer disease

A guide to density measurement excellence eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence